New tools could help doctors predict who will respond to chronic GVHD therapies

NCT ID NCT01902576

Ongoing Knowledge-focused Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study involves 383 people who have chronic graft-versus-host disease (GVHD) after a stem cell transplant. Researchers are developing and testing new ways to measure whether a treatment is working, including a symptom-based activity index and a score that predicts long-term success without treatment failure. The goal is to create better tools for future clinical trials and patient care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could provide doctors with better ways to measure if a chronic GVHD treatment is working, and help predict which patients will respond to which therapies.
What could go wrong: This is an observational study focused on developing measurement tools, not testing a new treatment. The tools may not prove accurate enough for widespread use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT VS HOST DISEASE

Contacts and locations

Locations

Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.